Glaukos (GKOS) to Release Earnings on Tuesday

Glaukos (NYSE:GKOS) is expected to be releasing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect Glaukos to post earnings of ($0.23) per share and revenue of $132.1570 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

Glaukos Price Performance

Glaukos stock opened at $109.51 on Friday. The stock has a market cap of $6.29 billion, a P/E ratio of -71.11 and a beta of 0.70. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average price is $114.64 and its two-hundred day moving average price is $98.00. Glaukos has a 52 week low of $73.16 and a 52 week high of $161.78.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total value of $536,350.00. Following the sale, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. This represents a 12.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Marc Stapley sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director owned 37,449 shares in the company, valued at $4,782,611.79. This trade represents a 28.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 329,655 shares of company stock valued at $37,752,234. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Glaukos

Hedge funds have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new stake in Glaukos during the fourth quarter worth approximately $128,000. Inspire Advisors LLC purchased a new position in shares of Glaukos in the 4th quarter valued at $299,000. Segall Bryant & Hamill LLC raised its stake in Glaukos by 4.7% during the 4th quarter. Segall Bryant & Hamill LLC now owns 131,404 shares of the medical instruments supplier’s stock worth $14,837,000 after acquiring an additional 5,914 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Glaukos by 9.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares during the last quarter. Finally, Exome Asset Management LLC boosted its stake in Glaukos by 15.9% in the fourth quarter. Exome Asset Management LLC now owns 31,471 shares of the medical instruments supplier’s stock valued at $3,553,000 after acquiring an additional 4,328 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GKOS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. BTIG Research raised their price target on shares of Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a report on Wednesday, January 28th. The Goldman Sachs Group reissued a “buy” rating and set a $138.00 price objective on shares of Glaukos in a report on Friday, January 9th. Stephens raised their target price on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 2nd. Finally, UBS Group boosted their target price on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $132.54.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.